Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

Inclusion Criteria:

• Pathologically (histologically or cytologically) proven diagnosis of NSCLC

• Planned initiation (within the 30 days after study registration) of fractionated (≥15 treatments) thoracic radiotherapy with concurrent chemotherapy. Expectedtreatment scenarios include:

• Definitive treatment of stage III disease (most common)

• Definitive treatment for locoregional recurrence of early stage disease

• Definitive treatment of unresectable stage II disease

• Preoperative treatment of stage III disease

• Postoperative treatment after incomplete resection (uncommon)

• Radical treatment for a patient with advanced/metastatic disease with the goalof achieving long-term thoracic disease control (e.g., oligometastatic diseasewhere metastases are addressed with resection or stereotactic radiotherapy)

• ECOG Performance Status 0-3 within 30 days prior to registration

• Age ≥ 18

• Ambulates independently or with a cane (use of a walker not permitted)

• Patients who already use wearable devices and/or smartphones that monitor physicalactivity are eligible for this trial. Patients must agree to wear the deviceprovided by the study.

• The patient or a legally authorized representative must provide study-specificinformed consent prior to study entry.

Exclusion Criteria:

• Patients with a history of another cancer that is expected to affect the toxicityprofile of thoracic chemoradiotherapy for NSCLC

• Patients receiving concurrent treatment for another cancer that is expected toaffect the toxicity profile of thoracic chemoradiotherapy

• Patients receiving thoracic radiotherapy without concurrent chemotherapy areineligible. Patients receiving concurrent chemotherapy and another form of systemictherapy (e.g., immunotherapy) are eligible. Patients receiving radiotherapy withconcurrent immunotherapy or targeted therapy but without chemotherapy are ineligible